Welcome to our dedicated page for Yield10 Bioscience news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on Yield10 Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Yield10 Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Yield10 Bioscience's position in the market.
Yield10 Bioscience, an agricultural bioscience company, will present at the Winter Wonderland - Best Ideas 2023 Virtual Conference from February 21-24, 2023. CEO Oliver Peoples, Ph.D., is set to speak on February 21 at 1:30 pm ET in a fireside chat hosted by Ben Klieve, CFA, of Lake Street Capital Markets. Investors registered for the conference can engage in one-on-one meetings with management. The presentation will be webcast live, with replay available. For more details, visit Yield10's website or register for the event.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) has announced a Memorandum of Understanding (MOU) with Mitsubishi Corporation to explore collaboration in supplying and marketing Camelina oil as a low-carbon feedstock for biofuels. The companies will conduct a feasibility study for the supply and offtake of Camelina oil from seed grown using Yield10's proprietary genetics. Additionally, they aim to study the development of PHA bioplastics derived from Camelina as a co-product. The non-binding MOU is set to expire at the end of 2023.
Yield10 Bioscience (Nasdaq:YTEN) reported a net loss of $3.5 million for Q3 2022, compared to a loss of $2.4 million in Q3 2021. The increase in losses is attributed to higher research and development expenses, which rose to $2.1 million. The company is focused on developing Camelina, a low-carbon feedstock for biofuels, with grower contracts for winter 2022/2023 in place. Yield10’s collaboration with Rothamsted Research for omega-3 technology has been extended, and they are ramping up seed production. As of Q3 2022, the company held $7.4 million in cash, forecasting a total cash usage of $12.0-$12.5 million for the year.
Yield10 Bioscience (Nasdaq: YTEN) has initiated its winter 2022/2023 field test and seed production program for Camelina across the U.S., Canada, Argentina, and Chile. The program includes over 20 test sites evaluating Camelina varieties for agronomical performance, seed yield, oil content, and herbicide tolerance. The company aims to produce commercial seed inventory for growers, focusing on developing herbicide-tolerant Camelina. This initiative targets crop diversification and aims to support the biofuel and animal feed markets.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced it will report its third quarter 2022 financial results on November 14, 2022. This will be followed by a management conference call at 4:30 p.m. ET to discuss the financial results and provide business updates. Interested parties can listen to the call via phone or live webcast. Yield10 focuses on developing improved Camelina varieties and aims to commercialize high-value seed products while discovering genetic traits for broader agriculture applications.
Yield10 Bioscience (NASDAQ:YTEN) will present at the MicroCap Rodeo's Windy City Roundup 2022 on October 12 at 3:30 pm CDT. This in-person conference runs from October 12-13 in Woburn, MA. Management will also hold one-on-one meetings during the event. The presentation will be available via live webcast and for replay. Yield10 is focused on developing Camelina varieties for high value seed products in agriculture, targeting renewable diesel and omega-3 oils. For more information, visit yield10bio.com.
Yield10 Bioscience announced the appointment of Willie Loh, Ph.D., to its Board of Directors, effective October 4, 2022. Previously serving as a Special Commercial and Technical Advisor, Dr. Loh brings extensive experience from his former role as Vice President of Market Development at Cargill's Global Edible Oils Solutions. His expertise will enhance Yield10's commercial strategy for Camelina, addressing the gap in global vegetable oil supply amidst rising demand. Dr. Loh has a strong academic background and a history of innovation in the agricultural sector.
Yield10 Bioscience has announced that Dr. Kristi Snell, the Chief Science Officer, will present at the International Symposium on Biopolymers (ISBP) 2022 Conference in Switzerland from September 12-16, 2022. Dr. Snell's presentation on September 16 will cover "Breakthroughs in Plant Based Polyhydroxybutyrate (PHB) Production," highlighting successful engineering of a bacterial pathway for PHB in Camelina seed. Yield10 aims for sustainable PHA bioplastic production, achieving over 10% PHB yield in seed, with plans for field trials in 2022/2023.
Yield10 Bioscience, an agricultural bioscience company, announced that President and CEO Oliver Peoples will present at the 24th Annual H.C. Wainwright Global Investment Conference on September 13, 2022, at 2:00 pm ET. The event runs from September 12 to 14, 2022, at the Lotte New York Palace Hotel. A live webcast of the presentation will be available on the company’s Investor Relations website. Yield10 focuses on high-value seed products, leveraging its Trait Factory technology to develop improved Camelina varieties and genetic traits for agriculture.
Yield10 Bioscience (YTEN) reported its second quarter 2022 financial results, highlighting progress in operationalizing its Camelina crop commercialization plan. The company targets over 1,000 acres for winter Camelina cultivation in North America. Despite a net loss of $3.4 million for the quarter and $6.8 million for the year-to-date, Yield10 maintains a cash position of $10.2 million. Ongoing challenges include increasing R&D expenses and dependence on external financing for sustainability. The company also discusses the impact of geopolitical uncertainty and COVID-19 on its operations.